Keros Therapeutics (KROS) Leases (2019 - 2025)
Keros Therapeutics (KROS) has disclosed Leases for 7 consecutive years, with $16.8 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Leases fell 12.52% year-over-year to $16.8 million, compared with a TTM value of $16.8 million through Dec 2025, down 12.52%, and an annual FY2025 reading of $16.8 million, down 12.52% over the prior year.
- Leases was $16.8 million for Q4 2025 at Keros Therapeutics, down from $17.5 million in the prior quarter.
- Across five years, Leases topped out at $19.8 million in Q3 2024 and bottomed at $447000.0 in Q3 2022.
- Average Leases over 5 years is $10.5 million, with a median of $15.2 million recorded in 2023.
- The sharpest move saw Leases crashed 36.14% in 2022, then surged 3405.37% in 2023.
- Year by year, Leases stood at $1.1 million in 2021, then skyrocketed by 1343.3% to $15.4 million in 2022, then fell by 0.43% to $15.3 million in 2023, then rose by 25.54% to $19.3 million in 2024, then fell by 12.52% to $16.8 million in 2025.
- Business Quant data shows Leases for KROS at $16.8 million in Q4 2025, $17.5 million in Q3 2025, and $18.1 million in Q2 2025.